Raanan Berger

14.3k total citations · 4 hit papers
160 papers, 7.2k citations indexed

About

Raanan Berger is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Raanan Berger has authored 160 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Oncology, 78 papers in Pulmonary and Respiratory Medicine and 40 papers in Molecular Biology. Recurrent topics in Raanan Berger's work include Cancer Immunotherapy and Biomarkers (41 papers), Prostate Cancer Treatment and Research (31 papers) and Renal cell carcinoma treatment (25 papers). Raanan Berger is often cited by papers focused on Cancer Immunotherapy and Biomarkers (41 papers), Prostate Cancer Treatment and Research (31 papers) and Renal cell carcinoma treatment (25 papers). Raanan Berger collaborates with scholars based in Israel, United States and Japan. Raanan Berger's co-authors include Laura Q.M. Chow, Jonathan D. Cheng, Shilpa Gupta, Jared Lunceford, Kumudu Pathiraja, Karl Heath, Joseph P. Eder, Christine K. Gause, Barbara Burtness and Tanguy Y. Seiwert and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Raanan Berger

153 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

2016 1.3k citations Tanguy Y. Seiwert, Barbara Burtness et al. The Lancet Oncology profile →
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

2016 1.1k citations Laura Q.M. Chow, Raanan Berger et al. profile →
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

2004 781 citations Pradip K. Majumder, Phillip G. Febbo et al. profile →
Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

2008 536 citations Raanan Berger, Avichai Shimoni et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Raanan Berger

Since Specialization

Citations

This map shows the geographic impact of Raanan Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raanan Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raanan Berger more than expected).

Fields of papers citing papers by Raanan Berger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raanan Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raanan Berger. The network helps show where Raanan Berger may publish in the future.

Co-authorship network of co-authors of Raanan Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Raanan Berger. A scholar is included among the top collaborators of Raanan Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raanan Berger. Raanan Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Modeling epithelial-mesenchymal transition in patient-derived breast cancer organoids 2024 ·Frontiers in Oncology ·(unknown), Rakefet Ben-Yishay, (unknown), (unknown), (unknown), Tehillah S. Menes, (unknown), (unknown), Nora Balint‐Lahat, (unknown), (unknown), Mohammad Adileh, Raanan Berger, Dana Ishay-Ronen	1
2	A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression 2024 ·Cancer Cell ·Pradip K. Majumder, Chiara Grisanzio, Fionnuala O’Connell, Marc Barry, Joseph Brito, Qing Xu, Isil Guney, Raanan Berger, Paula Herman, Rachel Bikoff, Giuseppe Fedele, Won‐Ki Baek, Shunyou Wang, Katharine Ellwood‐Yen, Hong Wu, Charles Sawyers, Sabina Signoretti, William C. Hahn, Massimo Loda, William R. Sellers	0
3	157 A transcriptomics-based response predictor identifies potential responders among patients with negative standard markers for response to immune checkpoint blockers 2023 ·SHILAP Revista de lepidopterología ·Gal Dinstag, (unknown), (unknown), Kenneth Aldape, Eytan Ruppin, Tuvik Beker, Raanan Berger, Ranit Aharonov	1
4	Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours 2022 ·European Journal of Cancer ·Ofer Margalit, Einat Shacham‐Shmueli, (unknown), Raanan Berger, Sharon Halperin, (unknown), E G Levin, Liraz Olmer, Gili Regev‐Yochay, Yaniv Lustig, Galia Rahav	5
5	Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study 2021 ·European Journal of Cancer ·Einat Shmueli, (unknown), Ofer Margalit, Raanan Berger, Sharon Halperin, (unknown), E G Levin, Itzchak Levy, Liraz Olmer, Gili Regev‐Yochay, Yaniv Lustig, Galia Rahav	31
6	231P Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199 2020 ·Annals of Oncology ·Jeffrey C. Goh, Josep M. Piulats, Marine Gross‐Goupil, Ulka N. Vaishampayan, Ronald de Wit, Tuomo Alanko, Satoshi Fukasawa, Ken‐ichi Tabata, (unknown), Raanan Berger, Haiyan Wu, (unknown), Charles Schloss, Johann S. de Bono, Emmanuel S. Antonarakis	2
7	JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) 2018 ·Annals of Oncology ·Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, Brian I. Rini, Laurence Albigès, Matthew T. Campbell, Christian Kollmannsberger, Sylvie Négrier, Mamoru Uemura, J.L. Lee, Howard Gurney, Raanan Berger, Manuela Schmidinger, James Larkin, Michael B. Atkins, (unknown), Paul B. Robbins, A. Chudnovsky, Alessandra di Pietro, Toni K. Choueiri	24
8	Tumor Evolution Inferred by Patterns of microRNA Expression through the Course of Disease, Therapy, and Recurrence in Breast Cancer 2016 ·Clinical Cancer Research ·Maya Dadiani, Noa Bossel Ben‐Moshe, Shani Paluch–Shimon, Gili Perry, (unknown), (unknown), (unknown), (unknown), (unknown), Ady Yosepovich, Einav Nili Gal‐Yam, Raanan Berger, Iris Barshack, Eytan Domany, Bella Kaufman	7
9	Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib 2016 ·Annals of Oncology ·Victoria Neiman, Daniel Keizman, David Sarid, J.-L. Lee, Avishay Sella, Maya Gottfried, (unknown), Mario A. Eisenberger, Michael A. Carducci, Victoria J. Sinibaldi, Eli Rosenbaum, (unknown), Avivit Neumann, Wilmosh Mermershtain, Keren Rouvinov, Raanan Berger, İbrahim Yıldız	0
10	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial breakdown → 2016 ·The Lancet Oncology ·Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra, Jared Weiss, Raanan Berger, Joseph P. Eder, Karl Heath, Terrill K. McClanahan, Jared Lunceford, Christine K. Gause, Jonathan D. Cheng, Laura Q.M. Chow	1275
11	Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers 2016 ·Breast Cancer Research and Treatment ·Shani Paluch–Shimon, Eitan Friedman, Raanan Berger, Moshe Z. Papa, Maya Dadiani, (unknown), Moshe Shabtai, Dov Zippel, Mordechai Gutman, Talia Golan, Ady Yosepovich, Raphael Catane, (unknown), Bella Kaufman	31
12	Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib? 2015 ·Cancer Research and Treatment ·Daniel Keizman, Keren Rouvinov, Avishay Sella, Maya Gottfried, (unknown), Jaeyeon Kim, Mario A. Eisenberger, Victoria J. Sinibaldi, Avivit Peer, Michael A. Carducci, Wilmosh Mermershtain, Raya Leibowitz‐Amit, Rony Weitzen, Raanan Berger	8
13	Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors. 2014 ·PubMed ·(unknown), Maya Gottfried, (unknown), Avivit Peer, Avivit Neumann, (unknown), Svetlana Kovel, Avishay Sella, Wilmosh Mermershtain, Keren Rouvinov, Ben Boursi, Rony Weitzen, Raanan Berger, Daniel Keizman	9
14	Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation 2014 ·Haematologica ·A. Nagler, Myriam Labopin, (unknown), Felicetto Ferrara, Miguel Á. Sanz, Dong Wu, (unknown), Simona Lapusan, Giuseppe Irrera, (unknown), Ana Berta Sousa, Carella Am, Norbert Vey, William Arcese, Avichai Shimoni, Raanan Berger, (unknown), Mohamad Mohty	29
15	Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma 2012 ·European Journal of Cancer ·Daniel Keizman, Maya Ish‐Shalom, Роберто Пили, Hans J. Hammers, Mario A. Eisenberger, Victoria J. Sinibaldi, Ben Boursi, (unknown), Maya Gottfried, (unknown), Avivit Peer, Svetlana Kovel, Avishay Sella, Raanan Berger, Michael A. Carducci	42
16	Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack 2008 ·Immunology ·Gal Markel, Rachel Seidman, Yifat Cohen, Michal J. Besser, (unknown), Avraham J. Treves, Arie Orenstein, Raanan Berger, Jacob Schachter	42
17	A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression 2008 ·Cancer Cell ·Pradip K. Majumder, Chiara Grisanzio, Fionnuala O’Connell, Marc Barry, Joseph Brito, Qing Xu, Isil Guney, Raanan Berger, Paula Herman, Rachel Bikoff, Giuseppe Fedele, Won‐Ki Baek, Shunyou Wang, Katharine Ellwood‐Yen, Hong Wu, Charles L. Sawyers, Sabina Signoretti, William C. Hahn, Massimo Loda, William R. Sellers	132
18	Computational Causal Reasoning Models of Mechanisms of Androgen Stimulation in Prostate Cancer 2006 ·PubMed ·Dexter Pratt, (unknown), Matthews, Phillip G. Febbo, Raanan Berger, (unknown), Joseph Levy, (unknown), Jin Sun, Brendon Ladd, Keith Elliston	2
19	Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells 2004 ·Cancer Research ·Raanan Berger, Phillip G. Febbo, Pradip K. Majumder, Jean J. Zhao, Sayan Mukherjee, Sabina Signoretti, Katrina Campbell, William R. Sellers, Thomas M. Roberts, Massimo Loda, Todd R. Golub, William C. Hahn	140
20	Demonstration of Thymopoietin Transcripts in Different Hematopoietic Cell Lines 1995 ·Acta Haematologica ·Raanan Berger, Livia Theodor, F. Brok‐Simoni, Hannah Ben‐Bassat, L. Trakhtenbrot, J. Shoham, Gideon Rechavi	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact